SSequencing.com operates a direct-to-consumer genetic testing platform that lets users buy DNA sequencing kits or upload raw data from other services and access a marketplace of over 100 apps to analyze their DNA. After uploading or obtaining data, users run apps (free, paid, or via Silver, Gold, or Platinum memberships) to generate reports on health, ancestry, nutrigenomics, and more, supported by tools like Genome Explorer and Next-Gen Rare Disease Screen. It stands out by offering a large, app-based marketplace and by allowing data from different providers, while emphasizing privacy (HIPAA compliant and not selling data without consent). The goal is to make genomic data accessible and understandable for individuals, supporting personalized preventive medicine and informed health decisions.
Work here?Claim your company
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
N/A
Total Funding
$4.9M
Headquarters
Pasadena, CA
Founded
2017
See people who can refer or advise you
Total Funding
$4.9M
Above
Industry Average
Funded Over
0 Rounds
Sequencing is now available on truemed for HSA and FSA payments. By Sequencing Team, The team of bioinformaticians, Genetic Health Coaches, and writers at Sequencing. Aug 20, 2026 Sequencing kits are HSA and FSA eligible, and now you have another way to pay with those funds. Sequencing has partnered with Truemed to offer HSA and FSA payment at checkout. For qualified customers, eligible savings average around 30 percent.* Here's what that means and how to start. What Sequencing gives you. Every Sequencing kit reads your whole genome at 30x depth from one easy at-home cheek swab. Your sample is processed in a CLIA-certified, CAP-accredited U.S. laboratory. It is designed for people of all ages, including infants. Choose your kit based on how many health area reports you want and how fast you want them: * Standard: 10 reports in about 6 to 8 weeks * Expedited: 20 reports in about 4 to 5 weeks * Ultra-Rapid: 30 reports in about 2 to 3 weeks Those reports deliver insights across 15,000+ diseases, conditions, traits, and medication responses. AI powered guidance helps you understand your results and prepare for more informed conversations with your provider. Your genome does not change. So the same DNA data can unlock new reports as science advances. Your data stays in a secure, HIPAA compliant account with lifetime access. What the Truemed option adds. Truemed gives you another way to put pretax dollars toward your kit. You can now apply HSA and FSA funds directly at checkout, alongside your usual payment options. For eligible customers, that can lower your cost by roughly 30 percent. How it works. * Checkout. Add your kit to your cart. Choose Truemed as your payment option. * Purchase. Pay with your HSA or FSA card. If you qualify, the purchase is complete. Frequently asked questions. Is Sequencing HSA or FSA eligible? Yes, all bundles are HSA and FSA eligible. Truemed is now available as a payment option at checkout for qualified customers. How much can I save with HSA or FSA funds? Eligible customers save an average of around 30 percent using pre-tax dollars. What do I get with the kit? Your whole genome sequenced at 30x, and your choice of three kits: Standard (10 reports), Expedited (20 reports), or Ultra-Rapid (30 reports). All include lifetime portal access to your DNA data. *Average savings estimated by Truemed. Truemed is for qualified customers. HSA/FSA tax savings vary. Learn more at truemed.com/disclosures.
DUBLIN, March 28, 2024 /PRNewswire/ -- The "Whole Genome and Exome Sequencing Markets by Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?The plummeting costs for Whole Genome Sequencing are creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2023
DUBLIN, Feb. 29, 2024 /PRNewswire/ -- The "Human Gene Sequencing Markets, Strategies & Trends - Forecasts by Application, by Technology, by Workflow, by Product, and by Country, with Executive and Consultant Guides - 2023 to 2027" report has been added to ResearchAndMarkets.com's offering.Will all newborns receive genetic testing at birth? What segments are growing fastest? Where are the opportunities now that sequencing has gone mainstream?The plummeting costs for Genome Sequencing is creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well funded players are racing for market share on a global stage. This report forecasts the market size out for five years. The report includes detailed breakouts for 14 countries and 5 regions.Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon
DUBLIN, Feb. 9, 2024 /PRNewswire/ -- The "Next-Generation Sequencing: Emerging Clinical Applications and Global Markets" report has been added to ResearchAndMarkets.com's offering.Since NGS platforms can sequence an entire genomic region or even an entire genome, a single test can examine hundreds or thousands of clinically important genetic variations. This means that one test can replace multiple conventional single-gene tests, providing an advantage in price and in the amount of precious sample needed for the test itself.NGS is often more accurate and reliable than existing diagnostics. This can result in better clinical outcomes. For example, NGS can increase the pregnancy success rates in in vitro fertilization applications. Also, in rare genetic diseases, NGS can increase the success rates for determining a molecular diagnosis.The NGS platform enables companies to expand the menu of disorders/diseases over time after initial launch of a test
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
We're working on gathering enough insights on this company, check back soon!
Industries
Company Size
51-200
Company Stage
N/A
Total Funding
$4.9M
Headquarters
Pasadena, CA
Founded
2017
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs